Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma

Brien, G. L., Remillard, D., Shi, J., Hemming, M. L., Chabon, J., Wynne, K., Dillon, E. T., Cagney, G., Van Mierlo, G., Baltissen, M. P., Vermeulen, M., Qi, J., Frohling, S., Gray, N. S., Bradner, J. E., Vakoc, C. R., Armstrong, S. A. (November 2018) Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife, 7. ISSN 2050-084x

[thumbnail of 2018.Brien.pdf]
Preview
PDF
2018.Brien.pdf - Published Version

Download (60MB) | Preview

Abstract

Synovial sarcoma tumours contain a characteristic fusion protein, SS18-SSX, which drives disease development. Targeting oncogenic fusion proteins presents an attractive therapeutic opportunity. However, SS18-SSX has proven intractable for therapeutic intervention. Using a domain-focused CRISPR screen we identified the bromodomain of BRD9 as a critical functional dependency in synovial sarcoma. BRD9 is a component of SS18-SSX containing BAF complexes in synovial sarcoma cells; and integration of BRD9 into these complexes is critical for cell growth. Moreover BRD9 and SS18-SSX co-localize extensively on the synovial sarcoma genome. Remarkably, synovial sarcoma cells are highly sensitive to a novel small molecule degrader of BRD9, while other sarcoma subtypes are unaffected. Degradation of BRD9 induces downregulation of oncogenic transcriptional programs and inhibits tumour progression in vivo. We demonstrate that BRD9 supports oncogenic mechanisms underlying the SS18-SSX fusion in synovial sarcoma and highlight targeted degradation of BRD9 as a potential therapeutic opportunity in this disease.

Item Type: Paper
Subjects: bioinformatics
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > DNA, RNA structure, function, modification
bioinformatics > genomics and proteomics > genetics & nucleic acid processing
bioinformatics > genomics and proteomics
Investigative techniques and equipment
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification > protein types > BET bromodomain coactivator protein
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification > protein types > BET bromodomain coactivator protein > Brd9
Investigative techniques and equipment > CRISPR-Cas9
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > DNA, RNA structure, function, modification > mRNA
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification > protein types
diseases & disorders > cancer > cancer types > sarcoma
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification > protein types > transcription factor
CSHL Authors:
Communities: CSHL labs > Vakoc lab
CSHL Cancer Center Program > Cancer Genetics and Genomics Program
Depositing User: Matthew Dunn
Date: 15 November 2018
Date Deposited: 27 Nov 2018 17:07
Last Modified: 07 Feb 2024 18:28
PMCID: PMC6277197
Related URLs:
URI: https://repository.cshl.edu/id/eprint/37485

Actions (login required)

Administrator's edit/view item Administrator's edit/view item